Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $68.00 at Wells Fargo & Company

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective increased by analysts at Wells Fargo & Company from $49.00 to $68.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 12.69% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Wedbush boosted their target price on Xenon Pharmaceuticals from $47.00 to $64.00 and gave the stock an “outperform” rating in a research report on Tuesday. Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Needham & Company LLC increased their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a report on Monday. Finally, Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $71.94.

Xenon Pharmaceuticals Stock Down 3.8%

Shares of NASDAQ XENE opened at $60.35 on Tuesday. The stock has a market capitalization of $5.02 billion, a P/E ratio of -13.84 and a beta of 0.91. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $63.95. The stock’s 50 day moving average price is $42.62 and its two-hundred day moving average price is $41.41.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the business posted ($0.84) earnings per share. On average, analysts anticipate that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Insider Activity at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of XENE. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at about $33,000. Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals in the 3rd quarter valued at about $39,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 3 topline data for azetukalner in focal onset seizures — Xenon said the X‑TOLE2 study met its primary endpoint with statistically significant seizure reduction, supporting an NDA path and broader indication potential. GlobeNewswire: Topline Data Reuters: Trial Met Main Goal
• Positive Sentiment: Deutsche Bank raised its target to $90 (≈43% upside vs. $62.76), reiterating a buy — this is a large upward revision that signals bullish institutional view on commercial potential. TickerReport
• Positive Sentiment: HC Wainwright raised its target to $74 (≈17.9% upside) and kept a buy rating — another institutional upgrade supporting momentum. Benzinga
• Positive Sentiment: Needham raised its target to $80 (≈27.5% upside) and Wedbush lifted its target to $64 (small upside), both moving to buy/outperform — analyst coverage is converging higher after the data. Benzinga
• Neutral Sentiment: Trading halt ahead of the announcement — Nasdaq temporarily halted XENE for news pending before the release, a common market mechanism that preceded the move. (No external link provided)
• Neutral Sentiment: Wide media coverage and intraday volatility — multiple outlets flagged a near‑50% intraday move as investors reacted to the trial readout, increasing attention and liquidity. 247wallst: Why XENE Soared
• Negative Sentiment: Proposed $500M common share offering — Xenon filed an underwritten offering (with a 30‑day upsize option for $75M). This could be dilutive and weigh on near‑term upside depending on pricing and timing. GlobeNewswire: Proposed Offering
• Negative Sentiment: Valuation and commercial execution cautions — analysts/commentators note a crowded antiseizure market, adverse event profile risks, and the possibility that today’s jump overshoots fundamentals. These are reasons some investors may take profits or avoid adding at current levels. Seeking Alpha: Valuation Concerns

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.